Consumers are increasingly seeking nutritionally enhanced products, unique flavours and packaging, and ethically sourced ingredients. Significant technological advancements and investments in product innovation by manufacturers are driving the overall market growth for plant-based protein alternatives. In Europe, this growth is largely due to the rising adoption of veganism and the flexitarian trend. During vegetable processing, certain activities generate large amounts of by-products, many of which are discarded by manufacturers. These legumes and their by-products contain substantial amounts of protein. Manufacturers using legumes and their by-products-based proteins in food formulations must comply with European Union (EU) regulations and standards to obtain market approval. For this study, the regulatory framework and novel food dossier application process were sourced from the official EU website (Europa), while relevant standards were obtained from the International Organisation for Standardisation (ISO) and European Committee for Standardisation (CEN)-European Committee for Electrotechnical Standardisation (CENELEC) website. This review provides an overview of protein extraction from legumes and their by-products, followed by an analysis of the legal requirements for processing, production, and commercialisation of these extracted proteins in food formulations. It addresses standardisation and relevant standards in areas such as characterisation and safety. Furthermore, the novel food dossier application process and the EU requirements for legume proteins, if considered novel in the EU, are discussed. This review aims to serve as a guide for manufacturers already using, or considering the use of, legume proteins in food formulations within the EU, providing essential insights for gaining market acceptance and regulatory approval for these ingredients, whether existing or novel. Further research is needed to explore the incorporation of proteins extracted from legume by-products into food formulations.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11550120 | PMC |
http://dx.doi.org/10.1016/j.heliyon.2024.e39821 | DOI Listing |
Curr Nutr Rep
January 2025
Departamento de Industrias, Facultad de Ciencias Exactas y Naturales, ITAPROQ (UBA-CONICET), Universidad de Buenos Aires, Intendente Güiraldes, s/n, Ciudad Universitaria, Buenos Aires, 1428, Argentina.
Purpose Of Review: This review aims to consolidate recent findings on the development and functional validation of berry-based foods while proposing guidelines for future advancements.
Recent Findings: Current investigations on berry-based functional foods (dairy and bakery products, snacks, etc.) emphasize their potential health benefits, including antioxidant effects, glycemic control, enzyme modulation, among others.
Pharmaceutics
January 2025
Department of Physical Sciences, Earth and Environment, University of Siena, 53100 Siena, SI, Italy.
(L.) DC., commonly known as Japanese pepper, is a deciduous shrub native to East Asia.
View Article and Find Full Text PDFPharmaceutics
January 2025
Department of Dermatology, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.
Phosphodiesterase-4 (PDE4) is involved in the synthesis of inflammatory cytokines that mediate several chronic inflammatory disorders, including psoriasis and atopic dermatitis. In recent years, the therapeutic armamentarium in dermatology has expanded with the introduction of PDE4 inhibitors, both in oral and topical formulations. PDE4 inhibitors have gained increasing interest due to their remarkable safety record and ease of prescription, as evidenced by the recent influx of literature detailing its off-label uses.
View Article and Find Full Text PDFPharmaceutics
January 2025
Pharmacy, Pharmaceutical Technology and Physico-Chemical Department, University of Barcelona, Av. Joan XXIII, 27-31, 08028 Barcelona, Spain.
This study explores the development and characterization of lyophilized chondroitin sulfate (CHON)-loaded solid lipid nanoparticles (SLN) as an innovative platform for advanced drug delivery. Solid lipid nanoparticles are increasingly recognized for their biocompatibility, their ability to encapsulate diverse compounds, their capacity to enhance drug stability, their bioavailability, and their therapeutic efficacy. CHON, a naturally occurring glycosaminoglycan with anti-inflammatory and regenerative properties, was integrated into SLN formulations using the hot microemulsion technique.
View Article and Find Full Text PDFPharmaceutics
January 2025
Institute of Chemistry Rosario, National Council for Scientific and Technical Research (IQUIR-CONICET), Rosario 2000, Argentina.
: Chagas disease is a neglected tropical disease caused by infection with the parasite . Benznidazole and nifurtimox are the only approved drugs for treating this condition, but their low aqueous solubility may lead to erratic bioavailability. This work aimed for the first time to formulate tablets of nifurtimox by hot melt extrusion coupled with 3D printing as a strategy to increase drug dissolution and the production of tablets with dosage on demand.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!